LH - Laboratory Corporation of America Holdings
NYSE
->
Healthcare
->
Diagnostics & Research
Burlington,
United States
Type: Equity
LH price evolution
LH
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $536.8 | $727.9 | $1930.6 | $393.9 |
| Short term investments | ||||
| Net receivables | $2098.7 | $2065 | $2042.6 | $3049.9 |
| Inventory | $474.6 | $461.1 | $487.8 | $481.4 |
| Total current assets | $3765.4 | $3954.2 | $5120.9 | $4695 |
| Long term investments | $26.9 | $39.5 | $67.2 | $65.8 |
| Property, plant & equipment | $2911.8 | $2820.5 | $2762.1 | $2944.1 |
| Goodwill & intangible assets | $9484.5 | $9607.5 | $9336.3 | $12028.3 |
| Total noncurrent assets | $12959.7 | $12931.8 | $12597.8 | $15505 |
| Total investments | $26.9 | $39.5 | $67.2 | $65.8 |
| Total assets | $16725.1 | $16886 | $17718.7 | $20200 |
| Current liabilities | ||||
| Accounts payable | $827.5 | $690.6 | $713.1 | $880.7 |
| Deferred revenue | $421.7 | $360.8 | $349.7 | $586.7 |
| Short long term debt | $1172 | $1159.7 | $462.7 | $488.7 |
| Total current liabilities | $3225.2 | $2900.8 | $2183.3 | $2885.6 |
| Long term debt | $4133.3 | $5170.2 | $5747.6 | $5802.6 |
| Total noncurrent liabilities | $5609.4 | $6092.7 | $6730.6 | $6953.6 |
| Total debt | $5954.2 | $6329.9 | $6210.3 | $6291.3 |
| Total liabilities | $8850.1 | $8993.5 | $8913.9 | $9839.2 |
| Shareholders' equity | ||||
| Retained earnings | $7888.2 | $8069.5 | $8836.2 | $10729.9 |
| Other shareholder equity | -$59.3 | -$208.8 | -$153.7 | -$444.2 |
| Total shareholder equity | $7875 | $7873.1 | $8785 | $10341.5 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $536.8 | $430 | $1472.7 | $1320.8 |
| Short term investments | ||||
| Net receivables | $2098.7 | $3017.4 | $2978.3 | $3016.6 |
| Inventory | $474.6 | $470.6 | $401.4 | $423.2 |
| Total current assets | $3765.4 | $4625 | $5330.5 | $5125.4 |
| Long term investments | $26.9 | $65.7 | $60.9 | $73.5 |
| Property, plant & equipment | $2911.8 | $2956.2 | $2815.4 | $2729.6 |
| Goodwill & intangible assets | $9484.5 | $12067.9 | $11694.4 | $11712.6 |
| Total noncurrent assets | $12959.7 | $15530.1 | $15054.9 | $14946.3 |
| Total investments | $26.9 | $65.7 | $60.9 | $73.5 |
| Total assets | $16725.1 | $20155.1 | $20385.4 | $20071.7 |
| Current liabilities | ||||
| Accounts payable | $827.5 | $934.8 | $621.3 | $638.9 |
| Deferred revenue | $421.7 | $582.1 | $558.5 | $506.5 |
| Short long term debt | $1172 | $492.8 | $199 | $575.4 |
| Total current liabilities | $3225.2 | $3078.5 | $2782.9 | $3078.5 |
| Long term debt | $4133.3 | $5122.4 | $6143.6 | $6181 |
| Total noncurrent liabilities | $5609.4 | $6961.1 | $7308.5 | $7612.8 |
| Total debt | $5954.2 | $6294.9 | $6342.6 | $6756.4 |
| Total liabilities | $8850.1 | $10058.5 | $10091.4 | $10691.3 |
| Shareholders' equity | ||||
| Retained earnings | $7888.2 | $10581.7 | $10456.8 | $9402.3 |
| Other shareholder equity | -$59.3 | -$493.2 | -$191.9 | -$161.9 |
| Total shareholder equity | $7875 | $10096.6 | $10273.4 | $9359.7 |
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3033.3 | $3056.8 | $3033.7 | $3777.9 |
| Cost of revenue | $2205.6 | $2191.5 | $2803.2 | |
| Gross Profit | $821.4 | $851.2 | $842.2 | $974.7 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $525.5 | $505.8 | $553.6 | |
| Total operating expenses | $592.1 | $598.9 | $575.9 | $633.7 |
| Operating income | $252.3 | $266.3 | $341 | |
| Income from continuing operations | ||||
| EBIT | $288.7 | $288.5 | $328.1 | |
| Income tax expense | $19.7 | $55.1 | $49.8 | $64.5 |
| Interest expense | -$42.5 | $50.3 | $49.8 | $50.7 |
| Net income | ||||
| Net income | -$167.1 | $183.3 | $188.9 | $212.9 |
| Income (for common shares) | $183.3 | $188.9 | $212.9 | |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $12161.6 | $14876.8 | $16120.9 | $13978.5 |
| Cost of revenue | $10491.7 | $10496.6 | $9025.7 | |
| Gross Profit | $3364.9 | $4385.1 | $5624.3 | $4952.8 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $1996.6 | $1952.1 | $1729.3 | |
| Total operating expenses | $2241.2 | $2611.2 | $2364.8 | $2507.4 |
| Operating income | $1773.9 | $3259.5 | $2445.4 | |
| Income from continuing operations | ||||
| EBIT | $1761.4 | $3336.5 | $2425.6 | |
| Income tax expense | $188.5 | $302 | $747.1 | $662.1 |
| Interest expense | -$172.2 | $180.3 | $212.1 | $207.4 |
| Net income | ||||
| Net income | $418 | $1279.1 | $2377.3 | $1556.1 |
| Income (for common shares) | $1279.1 | $2377.3 | $1556.1 | |
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $183.3 | $188.9 | $212.9 | |
| Operating activities | ||||
| Depreciation | $189.3 | $156.4 | $213.7 | |
| Business acquisitions & disposals | -$379.8 | -$137.1 | $0.2 | |
| Stock-based compensation | $34.4 | $26.7 | $40.6 | |
| Total cash flows from operations | $275.5 | $351.4 | $121.2 | |
| Investing activities | ||||
| Capital expenditures | -$104.9 | -$87.6 | -$93.9 | |
| Investments | -$3 | -$4.3 | -$6.1 | |
| Total cash flows from investing | -$1171.5 | -$487.6 | -$253.6 | -$99.7 |
| Financing activities | ||||
| Dividends paid | -$254 | -$63.9 | -$64.6 | -$64.4 |
| Sale and purchase of stock | -$1009.9 | $8.6 | $7.1 | |
| Net borrowings | $89.6 | |||
| Total cash flows from financing | -$59.3 | -$1097.2 | $1545 | -$60.6 |
| Effect of exchange rate | $9.9 | -$2.8 | $3.3 | $3 |
| Change in cash and equivalents | $106.8 | -$1312.1 | $1646.1 | -$36.1 |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $1279.1 | $2377.3 | $1556.1 | |
| Operating activities | ||||
| Depreciation | $828.3 | $940 | $825 | |
| Business acquisitions & disposals | -$1162.4 | -$496.9 | -$267.6 | |
| Stock-based compensation | $144.1 | $153.7 | $111.7 | |
| Total cash flows from operations | $1955.9 | $3109.6 | $2135.3 | |
| Investing activities | ||||
| Capital expenditures | -$481.9 | -$460.4 | -$381.7 | |
| Investments | -$12.2 | -$14.6 | -$39.1 | |
| Total cash flows from investing | -$1171.5 | -$1652.2 | -$884.6 | -$643.2 |
| Financing activities | ||||
| Dividends paid | -$254 | -$195.2 | ||
| Sale and purchase of stock | -$1100 | -$1664.2 | -$78.6 | |
| Net borrowings | -$375 | -$412.2 | ||
| Total cash flows from financing | -$59.3 | -$1322.2 | -$2065.8 | -$517.4 |
| Effect of exchange rate | $9.9 | -$24.2 | -$7.3 | $8.6 |
| Change in cash and equivalents | $106.8 | -$1042.7 | $151.9 | $983.3 |
News
|
Madison Mid Cap Fund Q1 2024 Investment Strategy Letter
Seeking Alpha
24 Apr 2024
|
|
We're Calling Up This Healthcare Company From the Bullpen
TheStreet.com
18 Apr 2024
|
|
Medline adds Epredia to lab portfolio
Denton Record-Chronicle
17 Apr 2024
|
|
Labcorp (LH) to Report Q1 Earnings: What's in the Cards?
Zacks via Yahoo Finance
16 Apr 2024
|
|
Laboratory Corporation of America Holdings (NYSE:LH) Has Announced A Dividend Of $0.72
Simply Wall St. via Yahoo Finance
15 Apr 2024
|
|
Jim Cramer’s 10 Favorite Healthcare Stock Picks in 2024
Insider Monkey via Yahoo Finance
13 Apr 2024
|
|
Labcorp's (LH) At-Home Mpox Testing Kit Gets the FDA's EUA Nod
Zacks via Yahoo Finance
12 Apr 2024
|
|
Myriad Genetics (MYGN) Announces Favorable Research Results
Zacks via Yahoo Finance
11 Apr 2024
|
|
Labcorp wins FDA emergency nod for monkeypox test (NYSE:LH)
Seeking Alpha
10 Apr 2024
|
|
Labcorp's (LH) Strategic Alliances Aid Amid Macroeconomic Woes
Zacks via Yahoo Finance
9 Apr 2024
|
Fundamentals
| Market cap | $16.64B |
|---|---|
| Enterprise value | $22.06B |
| Shares outstanding | 83.90M |
| Revenue | $12.90B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $418.00M |
| Revenue Q/Q | -17.44% |
| Revenue Y/Y | N/A |
| P/E ratio | 39.81 |
|---|---|
| EV/Sales | 1.71 |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 1.29 |
| P/B ratio | 2.10 |
| Book/Share | 94.57 |
| Cash/Share | 6.40 |
| EPS | $4.98 |
|---|---|
| ROA | 2.34% |
| ROE | 4.79% |
| Debt/Equity | 1.12 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.17 |
| Quick ratio | 1.02 |